Drug Manufacturers

The Health Ministry has proposed suspending manufacturing licences immediately after drugs fail critical quality tests, aiming to prevent unsafe medicines from remaining in circulation.

Updated On: 05 Nov 2026 | 12:04 AM IST

The proposed amendments seek to strengthen accountability in drug manufacturing by requiring qualified personnel for batch release and maintaining prescribed records

Updated On: 03 Nov 2026 | 8:28 PM IST

Demand for GLP-1 drugs such as semaglutide is exposing capacity gaps across peptide APIs, sterile fill-finish facilities, injector devices and glass cartridges

Updated On: 28 Jun 2026 | 10:38 PM IST

Oncology drugmaker says soaring platinum prices, higher import duties and lengthy import approvals have made production financially unviable, worsening shortages of key chemotherapy medicines

Updated On: 08 Jun 2026 | 4:11 PM IST

Regulator plans to cut delays by allowing direct submission of Form 40 applications to DCGI, aiming to improve efficiency in drug import approvals

Updated On: 09 Apr 2026 | 11:30 PM IST

Small pharma firms have flagged a steep surge in raw material and packaging costs amid global disruptions, warning of supply risks and seeking price controls

Updated On: 20 Mar 2026 | 12:05 PM IST

Experts say 2026 could be a crucial year for drug patents, with the likely emergence of fresh disputes over follow-on patents

Updated On: 15 Mar 2026 | 10:44 PM IST

Drug regulator warns pharma companies that obesity awareness drives linked to GLP-1 drugs could amount to misleading promotion of prescription medicines

Updated On: 11 Mar 2026 | 11:52 PM IST

Sun Pharma is transitioning its US business from low-margin generics to high-value specialty and innovative therapies.

Updated On: 11 Mar 2026 | 10:10 AM IST

In 2024, the ​USFDA issued a warning letter to Sun Pharma alleging 'significant violations' of 'current good manufacturing practice' ‍regulations for pharma made at the same production site in India

Updated On: 27 Jan 2026 | 10:47 AM IST

Cipla will exclusively market five Pfizer brands in India, adding ₹400-430 crore of established acute therapies to its portfolio without manufacturing risk

Updated On: 19 Dec 2025 | 8:09 PM IST

Novo Nordisk cut Wegovy prices by up to 37 per cent across different doses to compete with rival drug Mounjaro from Eli Lilly

Updated On: 27 Nov 2025 | 2:48 PM IST

The decision to turn down requests from drug manufacturers for more time came after it was highlighted that Sresan Pharmaceutical, the company that produced Coldrif, did not upgrade its facilities

Updated On: 17 Oct 2025 | 11:29 AM IST

Tegoprazan, a next-generation acid blocker, offers faster relief and lasting control for GERD, NERD, and gastric ulcers, addressing India's rising acid peptic disease burden

Updated On: 16 Sep 2025 | 7:14 PM IST

Top regulators like the US FDA and EMA are fast-tracking more Chinese drugs, granting priority review and breakthrough designations as they gain confidence in China's biotech innovation

Updated On: 14 Jul 2025 | 9:53 AM IST

The Health Ministry is working with states to allow immediate suspension of licences for drugs declared substandard by labs, following a key recommendation from Drugs Technical Advisory Board

Updated On: 26 Jun 2025 | 11:19 AM IST

India's top drugmakers are reportedly sitting on their highest cash reserves in at least five years, up over 120% from FY20

Updated On: 18 Jun 2025 | 4:41 PM IST

Serum Institute and DNDi sign MoU to develop and scale a dengue monoclonal antibody vaccine with Phase 3 trials in India, Brazil and other endemic countries

Updated On: 13 Jun 2025 | 6:42 PM IST

Agreement enables company to make 'strategic entry' in ophthalmology sector in the US, it says

Updated On: 15 Apr 2025 | 3:40 PM IST

Biocon Biologics on Tuesday said it has inked a settlement and licensing pact with Regeneron, paving the way to commercialise its biosimilar product Yesafili in the US. Yesafili, a vascular endothelial growth factor (VEGF) inhibitor used to treat several types of ophthalmology conditions, is a biosimilar of its reference product Eylea (aflibercept). Biocon Biologics and Regeneron executed the settlement agreement to dismiss the pending appeal at the US Court of Appeals for the Federal Circuit (USCAFC) and the pending litigation at the US District Court for the Northern District of West Virginia, Clarksburg Division, Biocon Biologics said in a statement. The agreement enables the company, a unit of Biocon Ltd, to launch its product in the US in the second half of 2026 or earlier in certain circumstances, it added. The terms of the settlement are confidential, it stated. "This settlement clears the path for Biocon Biologics to be among the first to bring a reliable, high-quality ..

Updated On: 15 Apr 2025 | 1:04 PM IST